Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.CERC · Entity 4936 | Director | June 15, 2021 | June 17, 2021 |
| CONTRAFECT CorpCFRX · Entity 116797 | Director | May 17, 2022 | May 18, 2022 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | December 07, 2016 | December 08, 2016 |
| NexImmune, Inc.NEXI · Entity 89921 | Director | July 05, 2023 | July 07, 2023 |
| PDS Biotechnology CorpEDGE · Entity 7939 | Director | March 15, 2019 | March 18, 2019 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2031-06-15 | Direct | 40,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 40,000 · Balance 40,000 F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date.
CONTRAFECT Corp
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17 | Direct | 42,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.
InspireMD, Inc.
Report date December 07, 2016 · Filed December 08, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2026-12-07 | Direct | 20,000 |
Reported balance
After 2016-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-07 · Grant · Acquired 20,000 · Balance 20,000 F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service.
NexImmune, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2033-07-04 | Direct | 44,983 |
Reported balance
After 2023-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 44,983 · Balance 44,983 |
PDS Biotechnology Corp
Report date March 15, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 678,075 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Exercise / conversion · Acquired 20,000 · Balance 678,075 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-15 · Exercise / conversion · Disposed 20,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.
F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.
F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 448,011 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 21,739 · Balance 448,011 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 21,739 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aegerion Pharmaceuticals, Inc.
Report date November 29, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 29,890 · Balance 0 F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2021-05-05 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 19,927 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2021-06-01 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 9,988 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2022-06-05 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-29 · Disposition to issuer · Disposed 12,854 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.73 · Expires 2023-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-29 · Disposition to issuer · Disposed 14,700 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.55 · Expires 2024-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-29 · Disposition to issuer · Disposed 5,012 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.98 · Expires 2025-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-29 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Aevi Genomic Medicine, LLC
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2023-01-02 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2024-01-02 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-06-22 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13 | IndirectBy the Sol J. Barer 2013 Grantor Retained Annuity Trust III | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-03 · Disposition to issuer · Disposed 74,912 · Balance 0 F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").
F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 25, 2017 Filed Jul 26, 2017 16:44 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseWarrants (Right to Buy) · Derivative | 20,000 | $0.01 Strike: $1.55 | $200.00 |
DisclosureSEC source: 0001209191-17-046312 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 per share · 20,000 shares Expires 2022-07-25 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:44 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 40,000 | $1.24 | $49,600.00 |
DisclosureSEC source: 0001209191-17-046312 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,933 Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 19:51 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | OtherWarrants (right To Purchase) · Derivative | 12,530 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001127602-17-023418 · form4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 12,530 shares Expires 2017-10-23 F2 · ownership.direct: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F2 · ownership.nature: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 19:51 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | OtherCommon Stock | 12,530 | $2.39 | $29,946.70 |
DisclosureSEC source: 0001127602-17-023418 · form4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 658,075 F1 · ownership.direct: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2017 Filed Aug 10, 2017 21:28 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantOption Award (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001144204-17-042180 · v473004_form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-06-22 Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 18:32 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (right To Purchase) · Derivative | 30,000 | $10.15 Strike: $10.15 | $304,500.00 |
DisclosureSEC source: 0001127602-17-021960 · form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-20 Read SEC document |
| April 28, 2017 Filed May 1, 2017 09:16 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 100,000 | $1.57 | $156,670.00 |
DisclosureSEC source: 0001192482-17-000111 · edgar.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,000 Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 08:40 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 100,000 | $1.54 | $154,340.00 |
DisclosureSEC source: 0001192482-17-000110 · edgar.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,000 Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 14:11 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001493152-16-015740 · form4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $17.98 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 7 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2025-06-26 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,012 | Not disclosed Strike: $32.55 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 6 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,012 shares Expires 2024-06-26 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,700 | Not disclosed Strike: $64.73 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 5 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,700 shares Expires 2023-06-26 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,854 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,854 shares Expires 2022-06-05 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,988 | Not disclosed Strike: $17.64 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,988 shares Expires 2021-06-01 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,927 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,927 shares Expires 2021-05-05 F2 · price: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:47 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerCommon Stock | 29,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-159821 · a4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.